Heramba Electric's Kiepe Electric Subsidiary Receives Order for SmartHybrid Battery Drive for Center-Cab Locomotive DE 18 from Vossloh Rolling Stock
September 19, 2024 08:30 ET
|
Heramba Electric plc
KIEPE equips Vossloh Rolling Stock's DE 18 center-cab locomotives with SmartHybrid battery power converters; eleven systems have already been delivered System integration by KIEPE replaces the...
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
September 18, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Heramba Electric's Kiepe Electric Subsidiary to Supply Traction Inverters for LOHR & SNCF's DRAISY Project Providing Revolutionary Very Light Train for the Region
September 16, 2024 09:00 ET
|
Heramba Electric plc
100% battery-powered light train DRAISY is intended to give new impulse to rural railway lines KIEPE provides the traction package for DRAISY with the Kiepe Traction Inverter (KTI) including the...
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
September 14, 2024 03:00 ET
|
Avacta Group
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024 03:00 ET
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Hybrid Exchange GRVT Secures 16 Top Market Makers and $3.3B Monthly Volume Ahead of Q4 Mainnet Launch
September 13, 2024 10:50 ET
|
GRVT Technologies Pte Ltd
SINGAPORE, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Hybrid cryptocurrency exchange GRVT (pronounced “gravity”), ZKsync’s first official Validium ZK Chain, is thrilled to announce its partnership with 16...
CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs
September 06, 2024 06:48 ET
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering....
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 05, 2024 11:54 ET
|
Immuron Limited
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on...
IMCD successfully issues a EUR 500 million rated bond
August 29, 2024 11:45 ET
|
IMCD N.V.
ROTTERDAM, The Netherlands (29 August 2024, 17:45 hrs CEST) – IMCD N.V. (“IMCD”) a leading distributor of speciality chemicals and food ingredients, today successfully issued a new EUR 500 million...
ImCheck obtient 20,18 millions d’euros de financement public dans le cadre du plan France 2030
August 29, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck reçoit un financement non-dilutif significatif afin d’accélérer l’avancement de deux programmes innovants, dans le traitement des cancer et des maladies infectieuses, en ligne avec l’ambition...